Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

Inclusion Criteria14

• Must have one of the following histologically and/or biochemically confirmed cancers:
• Cohort A: Esophageal, Gastroesophageal Junction, Gastric
• Cohort B: Small bowel
• Cohort C: Colorectal and appendiceal
• Cohort D: Biliary including gallbladder, intrahepatic and extrahepatic cholangiocarcinoma
• Cohort E: Hepatocellular carcinoma
• Cohort F: Pancreatic and ampullary
• Provision of signed and dated informed consent form.
• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Age ≥18 years at time of consent.
• Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.
• ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\]
• ≤ 5 progressing or new metastatic lesions.
• All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.